The shares of Freeport-McMoRan Inc. have increased by more than 0.84% this year alone. The shares recently went up by 7.42% or $1.32 and now trades at $19.12. The shares of Corcept Therapeutics Incorporated (NASDAQ:CORT), has slumped by -11.18% year to date as of 02/14/2018. The shares currently trade at $16.04 and have been able to report a change of -2.91% over the past one week.

The stock of Freeport-McMoRan Inc. and Corcept Therapeutics Incorporated were two of the most active stocks on Wednesday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.

**Next 5Y EPS Growth: 24.59% versus 71.00% **

When a company is able to grow consistently in terms of earnings at a high compound rate have the highest likelihood of creating value for its shareholders over time. Analysts have predicted that FCX will grow it’s earning at a 24.59% annual rate in the next 5 years. This is in contrast to CORT which will have a positive growth at a 71.00% annual rate. This means that the higher growth rate of CORT implies a greater potential for capital appreciation over the years.

**Profitability and Returns**

Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. FCX has an EBITDA margin of 20.38%, this implies that the underlying business of CORT is more profitable. The ROI of FCX is -14.20% while that of CORT is 18.10%. These figures suggest that CORT ventures generate a higher ROI than that of FCX.

**Cash Flow **

The value of a stock is ultimately determined by the amount of cash flow that the investors have available. Over the last 12 months, FCX’s free cash flow per share is a positive 7.77, while that of CORT is positive 0.01.

**Liquidity and Financial Risk**

The ability of a company to meet up with its short-term obligations and be able to clear its longer-term debts is measured using Liquidity and leverage ratios. The current ratio for FCX is 2.00 and that of CORT is 3.90. This implies that it is easier for FCX to cover its immediate obligations over the next 12 months than CORT. The debt ratio of FCX is 2.12 compared to 0.00 for CORT. FCX can be able to settle its long-term debts and thus is a lower financial risk than CORT.

**Valuation**

FCX currently trades at a forward P/E of 13.75, a P/B of 3.97, and a P/S of 1.69 while CORT trades at a forward P/E of 17.43, a P/B of 21.11, and a P/S of 14.60. This means that looking at the earnings, book values and sales basis, FCX is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.

**Analyst Price Targets and Opinions**

The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of FCX is currently at a -4.06% to its one-year price target of 19.93. Looking at its rival pricing, CORT is at a -25.4% relative to its price target of 21.50. This figure implies that over the next one year, CORT is a better investment.

When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), FCX is given a 2.80 while 2.00 placed for CORT. This means that analysts are more bullish on the outlook for FCX stocks.

**Insider Activity and Investor Sentiment**

Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for FCX is 1.78 while that of CORT is just 7.06. This means that analysts are more bullish on the forecast for FCX stock.

**Conclusion**

The stock of Freeport-McMoRan Inc. defeats that of Corcept Therapeutics Incorporated when the two are compared, with FCX taking 6 out of the total factors that were been considered. FCX happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, FCX is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for FCX is better on when it is viewed on short interest.